肠道微生物群与2型糖尿病并发症的关系
Relationship between Intestinal Microbiota and Complications of Type 2 Diabetes
DOI: 10.12677/ACM.2023.132194, PDF,    科研立项经费支持
作者: 孙佳乐：青海大学，青海 西宁；罗 玮*：青海省人民医院，青海 西宁
关键词: 肠道微生物群；2型糖尿病；糖尿病并发症；Gut Microbiota； Type 2 Diabetes； Diabetic Complications
摘要: 2型糖尿病(T2DM)是世界上常见的代谢性疾病之一，其发病率和流行率仍在不断上升。研究发现，肠道微生物群失调与代谢综合征之间存在紧密联系。肠道微生物群组成的改变与2型糖尿病及其并发症的发生及进展有着密切关系，肠道微生物群能够通过降低葡萄糖耐量来改善胰岛素抵抗。在本篇综述中，我们探讨了肠道微生物群紊乱与2型糖尿病进展及主要糖尿病大血管并发症(冠状动脉疾病)和微血管并发症(肾病、视网膜病变和神经病变)的改变，并探索通过肠道微生物群与益生菌为2型糖尿病及其并发症的治疗提供新的治疗策略。
Abstract: Type 2 diabetes (T2DM) is one of the most common metabolic diseases in the world, and its inci-dence rate and prevalence are still rising. Studies have found that there is a close relationship be-tween intestinal microbiota disorder and metabolic syndrome. The change of intestinal microbiota composition is closely related to the occurrence and progress of type 2 diabetes and its complica-tions. The intestinal microbiota can improve insulin resistance by reducing glucose tolerance. In this review, we discussed the progress of intestinal microbiota disorder and type 2 diabetes, and the changes of major vascular complications (coronary artery disease) and microvascular complica-tions (kidney disease, retinopathy and neuropathy) of diabetes, and explored new treatment strat-egies for type 2 diabetes and its complications through intestinal microbiota and probiotics.
文章引用：孙佳乐, 罗玮. 肠道微生物群与2型糖尿病并发症的关系[J]. 临床医学进展, 2023, 13(2): 1410-1415. https://doi.org/10.12677/ACM.2023.132194

参考文献

[1] Matijašić, M., Meštrović, T., Čipčić Paljetak, H.C., et al. (2020) Gut Microbiota beyond Bacteria—Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD. International Journal of Molecular Sciences, 21, Article No. 2668. [Google Scholar] [CrossRef] [PubMed]
[2] Jayasudha, R., Das, T., Kalyana, C.S., et al. (2020) Gut Mycobiomes Are Altered in People with Type 2 Diabetes Mellitus and Diabetic Retinopathy. PLOS ONE, 15, e243077. [Google Scholar] [CrossRef] [PubMed]
[3] Mazloom, K., Siddiqi, I. and Covasa, M. (2019) Probiotics: How Effective Are They in the Fight against Obesity? Nutrients, 11, Article No. 258. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, C., Li, Q. and Ren, J. (2019) Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection. Frontiers in Immunology, 10, Article 1873. [Google Scholar] [CrossRef] [PubMed]
[5] Williams, R., Karuranga, S., Malanda, B., et al. (2020) Global and Regional Estimates and Projections of Diabetes-Related Health Expenditure: Results from the International Diabetes Fed-eration Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 162, Article ID: 108072. [Google Scholar] [CrossRef] [PubMed]
[6] Silveira Rossi, J.L., Barbalho, S.M., de Araujo, R.R., et al. (2022) Metabolic Syndrome and Cardiovascular Diseases: Going beyond Traditional Risk Factors. Diabetes/Metabolism Research and Reviews, 38, e3502. [Google Scholar] [CrossRef] [PubMed]
[7] Iatcu, C.O., Steen, A. and Covasa, M. (2021) Gut Microbiota and Compli-cations of Type-2 Diabetes. Nutrients, 14, Article No. 166. [Google Scholar] [CrossRef] [PubMed]
[8] Lee, C.B., Chae, S.U., Jo, S.J., Jerng, U.M. and Bae, S.K. (2021) The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 22, Article No. 3566. [Google Scholar] [CrossRef] [PubMed]
[9] Chen, W., Zhang, M., Guo, Y, et al. (2021) The Profile and Function of Gut Microbiota in Diabetic Nephropathy. Diabetes, Metabolic Syndrome and Obesity, 14, 4283-4296. [Google Scholar] [CrossRef] 
[10] Tian, R., Liu, H., Feng, S., et al. (2021) Gut Microbiota Dysbiosis in Stable Coronary Artery Disease Combined with Type 2 Diabetes Mellitus Influences Cardiovascular Prognosis. Nutrition, Metabolism and Cardiovascular Diseases, 31, 1454-1466. [Google Scholar] [CrossRef] [PubMed]
[11] Zhu, Q., Gao, R., Zhang, Y., et al. (2018) Dysbiosis Signatures of Gut Microbiota in Coronary Artery Disease. Physiological Genomics, 50, 893-903. [Google Scholar] [CrossRef] [PubMed]
[12] Rodríguez-Morató, J. and Mat-than, N.R. (2020) Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascu-lar Disease. Current Atherosclerosis Reports, 22, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[13] Kim, S.M. and Song, I.H. (2020) The Clinical Impact of Gut Microbiota in Chronic Kidney Disease. Korean Journal of Internal Medicine, 35, 1305-1316. [Google Scholar] [CrossRef] [PubMed]
[14] Rukavina Mikusic, N.L., Kouyoumdzian, N.M. and Choi, M.R. (2020) Gut Microbiota and Chronic Kidney Disease: Evidences and Mechanisms That Mediate a New Communication in the Gastrointestinal-Renal Axis. Pflügers Archiv, 472, 303-320. [Google Scholar] [CrossRef] [PubMed]
[15] Meijers, B., Evenepoel, P. and Anders, H.-J. (2019) Intestinal Microbiome and Fitness in Kidney Disease. Nature Reviews Nephrology, 15, 531-545. [Google Scholar] [CrossRef] [PubMed]
[16] Chung, S.Y., Barnes, J.L. and Astroth, K.S. (2019) Gastrointesti-nal Microbiota in Patients with Chronic Kidney Disease: A Systematic Review. Advances in Nutrition, 10, 888-901. [Google Scholar] [CrossRef] [PubMed]
[17] Rodrigues, F.G., Ormanji, M.S., Heilberg, I.P., et al. (2021) Inter-play between Gut Microbiota, Bone Health and Vascular Calcification in Chronic Kidney Disease. European Journal of Clinical Investigation, 51, e13588. [Google Scholar] [CrossRef] [PubMed]
[18] Wei, H., Wang, L., An, Z., et al. (2021) QiDiTangShen Granules Modulated the Gut Microbiome Composition and Improved Bile Acid Proles in a Mouse Model of Diabetic Nephropathy. Biomedi-cine & Pharmacotherapy, 133, Article ID: 111061. [Google Scholar] [CrossRef] [PubMed]
[19] McFarlane, C., Krishnasamy, R., Stanton, T., et al. (2021) Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. Nutrients, 13, Article No. 4481. [Google Scholar] [CrossRef] [PubMed]
[20] Zhou, H., Peng, C., Huang, D.-S., et al. (2020) microRNA Expression Profiling Based on Microarray Approach in Human Diabetic Retinopathy: A Systematic Review and Meta-Analysis. DNA and Cell Biology, 39, 441-450. [Google Scholar] [CrossRef] [PubMed]
[21] Cecilia, O.-M., Jose, A.-C., Jose, N.-P., et al. (2019) Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology. Journal of Diabetes Research, 2019, Article ID: 8562408. [Google Scholar] [CrossRef] [PubMed]
[22] Ozkan, J., Willcox, M., Wemheuer, B., et al. (2019) Biogeography of the Human Ocular Microbiota. The Ocular Surface, 17, 111-118. [Google Scholar] [CrossRef] [PubMed]
[23] Das, T., Jayasudha, R., Chakravarthy, S., et al. (2021) Alterations in the Gut Bacterial Microbiome in People with Type 2 Diabetes Mellitus and Diabetic Retinopathy. Scientific Reports, 11, Article No. 2738. [Google Scholar] [CrossRef] [PubMed]
[24] Verma, A., Xu, K., Du, T., et al. (2019) Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice. Molecular Therapy—Methods & Clinical Development, 14, 161-170. [Google Scholar] [CrossRef] [PubMed]
[25] Lin, K., Fan, K., Mu, S. and Wang, S. (2022) Change in Cepha-locaudal Tumor Cavity Diameter after Transsphenoidal Surgery Is A Predictor of Diabetes Insipidus in Pituitary Adeno-ma. European Journal of Medical Research, 27, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[26] Garg, A., Chilakamarri, P. and Koo, B.B. (2021) Diagnostic and Treatment Considerations in Restless Legs Syndrome Complicated by Diabetic Neuropathy. Current Diabetes Reports, 21, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[27] Paul, S., Ali, A. and Katare, R. (2020) Molecular Complexities Underlying the Vascular Complications of Diabetes Mellitus—A Comprehensive Review. Journal of Diabetes and Its Complications, 34, Article ID: 107613. [Google Scholar] [CrossRef] [PubMed]
[28] Preguica, I., Alves, A., Nunes, S., et al. (2021) Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy. Nutrients, 12, Article No. 250. [Google Scholar] [CrossRef] [PubMed]
[29] Hicks, C.W. and Selvin, E. (2019) Epidemiology of Peripheral Neuropa-thy and Lower Extremity Disease in Diabetes. Current Diabetes Reports, 19, Article No. 86. [Google Scholar] [CrossRef] [PubMed]
[30] Pathak, R., Sachan, N. and Chandra, P. (2022) Mechanistic Ap-proach towards Diabetic Neuropathy Screening Techniques and Future Challenges: A Review. Biomedicine & Pharma-cotherapy, 150, Article ID: 113025. [Google Scholar] [CrossRef] [PubMed]
[31] Rolim, L.C., da Silva, E.M., Flumignan, R.L., Abreu, M.M. and Dib, S.A. (2019) Acetyl-L-Carnitine for the Treatment of Diabetic Peripheral Neuropathy. Cochrane Database of Sys-tematic Reviews, 6, Article No. D11265. [Google Scholar] [CrossRef] 
[32] Wang, Y., Ye, X., Ding, D. and Lu, Y. (2020) Character-istics of the Intestinal Flora in Patients with Peripheral Neuropathy Associated with Type 2 Diabetes. Journal of Interna-tional Medical Research, 48. [Google Scholar] [CrossRef] [PubMed]
[33] Zaharuddin, L., Mokhtar, N.M., Muhammad Nawawi, K.N. and Ali, R.A.R. (2019) A Randomized Double-Blind Placebo-Controlled Trial of Probiotics in Post-Surgical Colorectal Can-cer. BMC Gastroenterology, 19, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
[34] Fang, Y., Zhang, C., Shi, H., et al. (2021) Characteristics of the Gut Microbiota and Metabolism in Patients with Latent Autoimmune Diabetes in Adults: A Case-Control Study. Diabe-tes Care, 44, 2738-2746. [Google Scholar] [CrossRef] [PubMed]
[35] Lee, Y.-S., Lee, D., Park, G.-S., et al. (2021) Lactobacillus plantarum HAC01 Ameliorates Type 2 Diabetes in High-Fat Diet and Streptozotocin-Induced Diabetic Mice in Association with Modulating the Gut Microbiota. Food & Function, 12, 6363-6373. [Google Scholar] [CrossRef] 
[36] Watanabe, A., Tochio, T., Kadota, Y., et al. (2021) Supplementation of 1-Kestose Modulates the Gut Microbiota Composition to Ameliorate Glucose Metabolism in Obesity-Prone Hosts. Nu-trients, 13, Article No. 2983. [Google Scholar] [CrossRef] [PubMed]

为你推荐